Reduced Shannon index indicates lower alpha-diversity in the gut microbiota of patients with primary biliary cholangitis
Gut Microbiota Differences Linked to Primary Biliary Cholangitis
This meta-analysis of 1,057 participants found that patients with primary biliary cholangitis have significantly lower Shannon index values …
A large review of patient data shows that people with primary biliary cholangitis have significantly lower gut bacterial diversity than heal…
Combination therapy with fibrates and ursodeoxycholic acid improves biochemical markers in primary biliary cholangitis patients across multiple studies
Combination therapy improves biochemical markers in primary biliary cholangitis
An umbrella meta-analysis of meta-analyses involving 3,276 patients shows that adding fibrates to ursodeoxycholic acid significantly lowers …
Combining fibrates with ursodeoxycholic acid improves liver markers in primary biliary cholangitis patients, though survival data remain unc…
Systematic review shows high fatigue and pruritus prevalence in primary biliary cholangitis patients
Half of liver disease patients battle severe fatigue and itching
This systematic review and meta-analysis evaluated symptom burden in 13178 patients with primary biliary cholangitis. Fatigue affected 51% o…
Over half of patients with primary biliary cholangitis face severe fatigue and itching, yet most never get proper treatment for these sympto…
PPAR Agonists Reduce Pruritus in PBC: Meta-Analysis of 660 Patients
New drugs ease itch for patients whose current treatment fails
This systematic review and meta-analysis of 660 patients with primary biliary cholangitis and inadequate response to UDCA found that PPAR ag…
A review of six hundred sixty patients found new medicines significantly reduced itch scores in people with primary biliary cholangitis who …
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis
Fatty liver makes autoimmune hepatitis and PBC worse, but not PSC
This systematic review and meta-analysis of 19,898 patients with autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing c…
A large review found fatty liver is common in autoimmune liver diseases and makes outcomes worse for some patients, but not others.
Narrative review on T cell subsets in primary biliary cholangitis
New Liver Drug Targets Hidden Immune Cells
This narrative review synthesizes evidence on T cell subsets in primary biliary cholangitis.
Stopping the wrong immune cells could finally stop liver disease for those who do not respond to standard care.
Seladelpar shows improved composite endpoint and ALP reduction in PBC with compensated cirrhosis
New Drug Helps Liver Disease Patients With Cirrhosis
A phase 3 RCT program (RESPONSE and ASSURE studies) in patients with primary biliary cholangitis and compensated cirrhosis found seladelpar …
A new drug lowers liver stress markers in patients with cirrhosis, offering hope where older medicines often failed to stop disease progress…
Non-cirrhotic portal fibrosis identified in 32.6% of pre-cirrhotic primary biliary cholangitis patients in a retrospective analysis
Hidden Liver Damage Found in Early PBC
This retrospective analysis examined 92 biopsy-proven pre-cirrhotic primary biliary cholangitis (PBC) patients to characterize non-cirrhotic…
Many people with primary biliary cholangitis develop hidden liver damage called non-cirrhotic portal fibrosis before permanent scarring begi…
Questions about Primary biliary cholangitis
What T cell subsets are involved in primary biliary cholangitis?
Multiple T cell subsets are involved in PBC, including CD4+ Th17/Treg imbalance, CD8+ T cells, Tfh, Tph, and unconventional T cells like γδ T, MAIT, and iNKT cells.
Full answer →Can seladelpar improve liver function in primary biliary cholangitis?
Yes, seladelpar improves liver function in primary biliary cholangitis by reducing alkaline phosphatase (ALP) and bilirubin levels, especially in patients with compensated cirrhosis.
Full answer →Do PPAR agonists help reduce itching in primary biliary cholangitis?
Yes, PPAR agonists (bezafibrate, elafibranor, seladelpar) significantly reduce itching in primary biliary cholangitis, especially in those with moderate-to-severe symptoms.
Full answer →What percentage of primary biliary cholangitis patients experience pruritus symptoms?
About one-third, or 33%, of patients with primary biliary cholangitis experience pruritus, which is the second most common symptom after fatigue.
Full answer →How common is severe fatigue among patients with primary biliary cholangitis?
Severe fatigue affects about 20-23% of patients with primary biliary cholangitis, based on systematic reviews and large cohort studies.
Full answer →